R&D News | pharmaphorum

News

AHA: Cash for drug adherence study has disappointing result

People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.

News

Pfizer, Metsera $10bn marriage back on after rough patch

Pfizer has won the battle for obesity drug developer Metsera, after rival Novo Nordisk said that it would not increase its bid above $10bn.

News

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Lilly reports 20% weight loss with amylin-targeting drug

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

Novo Nordisk fights back with oral GLP-1 data in obesity

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.

AHA: Cash for drug adherence study has disappointing result

Pfizer, Metsera $10bn marriage back on after rough patch

Intellia shares fall after hospitalised CRISPR patient dies

Braveheart, AAVantgarde rounds head recent biofinancings

Lilly reports 20% weight loss with amylin-targeting drug

Novo Nordisk fights back with oral GLP-1 data in obesity

AI, start-ups, and the future of human health: AION Labs’ Ma...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks